Skip to main content
Erschienen in: Annals of Surgical Oncology 3/2009

01.03.2009 | Laboratory and Translational Research

Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells

verfasst von: Jie Li, MD, Ni Hou, MD, PhD, Ahmad Faried, MD, PhD, Soichi Tsutsumi, MD, PhD, Toshiyuki Takeuchi, MD, PhD, Hiroyuki Kuwano, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

5-fluorouracil-(5-FU)-based adjuvant chemotherapy is widely used for the treatment of colorectal cancer. However, 5-FU resistance in the course of treatment has become more common. Therefore, new therapeutic strategies and/or new adjuvant drugs still need to be explored.

Methods

Two colon-cancer-derived cell lines, colon26 and HT29, were used to investigate the effect of 5-FU, 3-methyladenine (3-MA, an autophagy inhibitor), or their combination on apoptotic cell death and autophagy. MTT assay, Hochest plus propidium iodide (PI) staining, and DNA fragmentation assay were used to observe apoptosis. Meanwhile, monodansylcadaverine (MDC) was used to detect autophagy. Finally, immunoblotting assay was used to explore the molecular change that occurred.

Results

We observed the apoptosis induced by 5-FU in colon cancer cells. Meanwhile, autophagy was also stimulated. The combination treatment of 3-MA and 5-FU significantly increased the apoptotic cell death. By isolating the subcellular fractions of mitochondria and cytosol, we observed that the release of cytochrome c was increased in combination-treated cells. Cytochrome c resulted in the activation of caspase-3, thus activating PARP. Moreover, the anti-apoptotic protein, Bcl-xL, was significantly downregulated by 3-MA.

Conclusions

Our results suggest that 5-FU-induced apoptosis in colon cancer cells can be enhanced by the inhibitor of autophagy, 3-MA. Autophagy might play a role as a self-defense mechanism in 5-FU-treated colon cancer cells, and its inhibition could be a promising strategy for the adjuvant chemotherapy of colon cancer.
Literatur
1.
Zurück zum Zitat Xu R, Zhou B, Fung PCW, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol. 2006;21:867–72.PubMed Xu R, Zhou B, Fung PCW, Li X. Recent advances in the treatment of colon cancer. Histol Histopathol. 2006;21:867–72.PubMed
2.
Zurück zum Zitat Chau I, Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev. 2002;28:223–36.PubMedCrossRef Chau I, Cunningham D. Adjuvant therapy in colon cancer: current status and future directions. Cancer Treat Rev. 2002;28:223–36.PubMedCrossRef
3.
Zurück zum Zitat Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol. 2006;17:1347–59.PubMedCrossRef Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol. 2006;17:1347–59.PubMedCrossRef
4.
Zurück zum Zitat Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg. 2006;191:517–26.PubMedCrossRef Huerta S, Goulet EJ, Livingston EH. Colon cancer and apoptosis. Am J Surg. 2006;191:517–26.PubMedCrossRef
5.
Zurück zum Zitat Nordman IC, Iyer S, Joshua AM, Clarke SJ. Advance in the adjuvant treatment of colorectal cancer. ANZ J Surg. 2006;76:373–80.PubMedCrossRef Nordman IC, Iyer S, Joshua AM, Clarke SJ. Advance in the adjuvant treatment of colorectal cancer. ANZ J Surg. 2006;76:373–80.PubMedCrossRef
6.
Zurück zum Zitat Wils J, O’Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol. 2001;12:13–22.PubMedCrossRef Wils J, O’Dwyer P, Labianca R. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. Ann Oncol. 2001;12:13–22.PubMedCrossRef
7.
Zurück zum Zitat Giacchetti BS, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–47.PubMed Giacchetti BS, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136–47.PubMed
8.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRef Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355:1041–7.PubMedCrossRef
9.
Zurück zum Zitat Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.PubMedCrossRef Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330–8.PubMedCrossRef
10.
Zurück zum Zitat Grem JL. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299–313.PubMedCrossRef Grem JL. 5-fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs. 2000;18:299–313.PubMedCrossRef
12.
Zurück zum Zitat Petiot A, Ogier-Denis E, Blommaart EFC, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3′ kinases are involved in signaling pathways that control macroautophagy in HT–29 cells. J Biol Chem. 2000;275:992–8.PubMedCrossRef Petiot A, Ogier-Denis E, Blommaart EFC, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3′ kinases are involved in signaling pathways that control macroautophagy in HT–29 cells. J Biol Chem. 2000;275:992–8.PubMedCrossRef
13.
Zurück zum Zitat Yan CH, Liang ZQ, Gu ZL, Yang YP, Reid P, Qin ZH. Contributions of autophagic and apoptotic mechanisms to CrTX induced death of K562 cells. Toxicon. 2006;47:521–30.PubMedCrossRef Yan CH, Liang ZQ, Gu ZL, Yang YP, Reid P, Qin ZH. Contributions of autophagic and apoptotic mechanisms to CrTX induced death of K562 cells. Toxicon. 2006;47:521–30.PubMedCrossRef
14.
Zurück zum Zitat Cui Q, Tashiro S, Onodera S, Ikejima T. Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci. 2006;101:230–9.PubMedCrossRef Cui Q, Tashiro S, Onodera S, Ikejima T. Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci. 2006;101:230–9.PubMedCrossRef
15.
Zurück zum Zitat Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717–21.PubMedCrossRef Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290:1717–21.PubMedCrossRef
16.
Zurück zum Zitat Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell B. 2004;36:2445–62.CrossRef Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. Int J Biochem Cell B. 2004;36:2445–62.CrossRef
17.
Zurück zum Zitat Ng G, Huang JX. The significance of autophagy in cancer. Mol Carcinogen. 2005;43:183–7.CrossRef Ng G, Huang JX. The significance of autophagy in cancer. Mol Carcinogen. 2005;43:183–7.CrossRef
18.
Zurück zum Zitat Ogier-Denis E, Codogno P. Autophagy: a barrier or an adaptive response to cancer. BBA-Rev Cancer. 2003;1603:113–28. Ogier-Denis E, Codogno P. Autophagy: a barrier or an adaptive response to cancer. BBA-Rev Cancer. 2003;1603:113–28.
19.
Zurück zum Zitat Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5:726–34.PubMedCrossRef Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5:726–34.PubMedCrossRef
20.
Zurück zum Zitat Hoorens A, Casteele MV, Klöppel G, Pipeleers D. Glucose promotes survival of rat pancreatic cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest. 1996;98:1568–74.PubMedCrossRef Hoorens A, Casteele MV, Klöppel G, Pipeleers D. Glucose promotes survival of rat pancreatic cells by activating synthesis of proteins which suppress a constitutive apoptotic program. J Clin Invest. 1996;98:1568–74.PubMedCrossRef
21.
Zurück zum Zitat Munafó DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci. 2001;114:3619–29.PubMed Munafó DB, Colombo MI. A novel assay to study autophagy: regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci. 2001;114:3619–29.PubMed
22.
Zurück zum Zitat Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic cell death in breast cancer cells following DNA damage. Cell Death Differ. 2006;22: 1–11. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A. Autophagy delays apoptotic cell death in breast cancer cells following DNA damage. Cell Death Differ. 2006;22: 1–11.
23.
Zurück zum Zitat Biederbick A, Kern HF, Elsasser HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol. 1995;66:3–14.PubMed Biederbick A, Kern HF, Elsasser HP. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol. 1995;66:3–14.PubMed
24.
Zurück zum Zitat Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, et al. Role of Bcl–2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol. 2004;6:1221–8.PubMedCrossRef Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, et al. Role of Bcl–2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol. 2004;6:1221–8.PubMedCrossRef
25.
Zurück zum Zitat Herman-Antosiewicz A, Johnson DE, Singh SV. Sulforaphane causes autophagy to inhibit release of cytochrome c and apoptosis in human prostate cancer cells. Cancer Res. 2006;66:5828–35.PubMedCrossRef Herman-Antosiewicz A, Johnson DE, Singh SV. Sulforaphane causes autophagy to inhibit release of cytochrome c and apoptosis in human prostate cancer cells. Cancer Res. 2006;66:5828–35.PubMedCrossRef
26.
Zurück zum Zitat Klionsky DJ, Levine B. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463–77.PubMedCrossRef Klionsky DJ, Levine B. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell. 2004;6:463–77.PubMedCrossRef
27.
Zurück zum Zitat Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6.PubMedCrossRef Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6.PubMedCrossRef
28.
Zurück zum Zitat Qu XP, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809–20.PubMed Qu XP, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809–20.PubMed
29.
Zurück zum Zitat Ding WX, Ni HM, Gao WT, et al. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem. 2007;282:4702–10.PubMedCrossRef Ding WX, Ni HM, Gao WT, et al. Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival. J Biol Chem. 2007;282:4702–10.PubMedCrossRef
30.
Zurück zum Zitat Bauvy C, Gane P, Arico S, Codogon P, Ogier-Denis E. Autophagy delays Sulindac Sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res. 2001;268:139–49.PubMedCrossRef Bauvy C, Gane P, Arico S, Codogon P, Ogier-Denis E. Autophagy delays Sulindac Sulfide-induced apoptosis in the human intestinal colon cancer cell line HT-29. Exp Cell Res. 2001;268:139–49.PubMedCrossRef
31.
Zurück zum Zitat Kanzawa T, Germano IM, Komata T, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004;11:448–57.PubMedCrossRef Kanzawa T, Germano IM, Komata T, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 2004;11:448–57.PubMedCrossRef
32.
Zurück zum Zitat Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001;61:439–44.PubMed Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001;61:439–44.PubMed
33.
Zurück zum Zitat Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103–8.PubMed Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63:2103–8.PubMed
34.
35.
Zurück zum Zitat Bursch W, Ellinger A, Kienzl H, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI164 384 in human mammary carcinoma cells (MCF–7) in culture: the role of autophagy. Carcinogenesis. 1996;17:1595–607.PubMedCrossRef Bursch W, Ellinger A, Kienzl H, et al. Active cell death induced by the anti-estrogens tamoxifen and ICI164 384 in human mammary carcinoma cells (MCF–7) in culture: the role of autophagy. Carcinogenesis. 1996;17:1595–607.PubMedCrossRef
36.
Zurück zum Zitat Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66:10040–7.PubMedCrossRef Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66:10040–7.PubMedCrossRef
37.
Zurück zum Zitat Iwamaru A, Kondo Y, Iwado E, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007;26:1840–51.PubMedCrossRef Iwamaru A, Kondo Y, Iwado E, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene. 2007;26:1840–51.PubMedCrossRef
38.
Zurück zum Zitat Zhu HB, Guo W, Zhang LD, et al. Bcl-xL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther. 2005;4:451–6.PubMedCrossRef Zhu HB, Guo W, Zhang LD, et al. Bcl-xL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther. 2005;4:451–6.PubMedCrossRef
39.
Zurück zum Zitat Tsujimoto Y. Cell death regulation by the Bcl–2 protein family in the mitochondria. J Cell Physiol. 2003;195:158–67.PubMedCrossRef Tsujimoto Y. Cell death regulation by the Bcl–2 protein family in the mitochondria. J Cell Physiol. 2003;195:158–67.PubMedCrossRef
40.
Zurück zum Zitat Pattingre S, Tassa A, Qu XP, et al. Bcl-2 antiapoptotic proteins inhibit beclin 1-dependent autophagy. Cell. 2005;122:927–39.PubMedCrossRef Pattingre S, Tassa A, Qu XP, et al. Bcl-2 antiapoptotic proteins inhibit beclin 1-dependent autophagy. Cell. 2005;122:927–39.PubMedCrossRef
Metadaten
Titel
Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells
verfasst von
Jie Li, MD
Ni Hou, MD, PhD
Ahmad Faried, MD, PhD
Soichi Tsutsumi, MD, PhD
Toshiyuki Takeuchi, MD, PhD
Hiroyuki Kuwano, MD, PhD
Publikationsdatum
01.03.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 3/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0260-0

Weitere Artikel der Ausgabe 3/2009

Annals of Surgical Oncology 3/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.